Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Fluicell AB's PE Ratio without NRI is 14.40. Fluicell AB's 5-Year EBITDA growth rate is 46.00%. Therefore, Fluicell AB's PEG Ratio for today is 0.31.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Fluicell AB's PEG Ratio or its related term are showing as below:
FRA:5J90'
s PEG Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.33
Current: 0.33
During the past 11 years, Fluicell AB's highest PEG Ratio was 0.33. The lowest was 0.00. And the median was 0.00.
FRA:5J90's PEG Ratio is ranked better than 87% of 100
companies
in the Biotechnology industry
Industry Median: 1.645
vs FRA:5J90: 0.33
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Fluicell AB PEG Ratio Related Terms
Fluicell AB PEG Ratio Historical Data
* Premium members only.
The historical data trend for Fluicell AB's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5J90 vs VRTX, REGN, MRNA: PEG Ratio Comparison
For the Biotechnology subindustry, Fluicell AB's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Fluicell AB's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Fluicell AB (FRA:5J90) has a PEG Ratio of 0.31 as of Sep. 08, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Fluicell AB and its competitors. According to the industry distribution chart, Fluicell AB ranks #13 out of 100 companies in the Biotechnology industry, placing it in the top 13%.
Is Fluicell AB's PEG Ratio too high?
Fluicell AB's current PEG Ratio is 0.31. The Biotechnology industry median PEG Ratio is 1.65. Fluicell AB's value of 0.31 is 81.2% below this industry median. Based on the distribution chart, Fluicell AB ranks #13 out of 100 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fluicell AB has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #13 out of 100 companies for PEG Ratio. This places Fluicell AB in the top 13% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.65. Fluicell AB's value of 0.31 is 81.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.65, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fluicell AB's current PEG Ratio of 0.31 is 81.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Fluicell AB and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current PEG Ratio is 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (FRA:5J90) is currently considered Possible Value Trap. The stock's GF Value™ is €6.64, compared to a current price of €2.75 — trading 58.6% below its estimated fair value. The current PEG Ratio is 0.31 and 81.2% below the Biotechnology industry median of 1.65. Fluicell AB's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Fluicell AB (FRA:5J90), the current PEG Ratio is 0.31 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (FRA:5J90) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of €2.75 is trading 58.6% below its estimated GF Value™ of €6.64.
GuruFocus considers Fluicell AB to be Possible Value Trap.
Key valuation signals for FRA:5J90:
PEG Ratio: 0.31
GF Value™: €6.64 vs. price of €2.75 (58.6% below fair value)
Industry Position: 81.2% below the Biotechnology median (#13 of 100)
No single metric tells the full story. See the FRA:5J90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
54GF Score
Get the complete analysis for FRA:5J90
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5J90 has been successfully added to your 
